Proactive Research Analyst Daniel Appiah gives the highlights from his latest research note on UK-based medical device company Creo Medical Group PLC (AIM:CREO).
Creo recently announced that the medical device company’s Speedboat Inject product was used for the first time in an upper gastrointestinal (GI) procedure in Europe, a major milestone for the business.
Appiah says Creo is “looking very well” and gives his take on what recent developments are likely to mean for the company’s financials.
#ProactiveInvestors #CREO #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
source